To investigate the effect of dapagliflozin combined with metformin on oxidative stress and glucose and lipid metabolism in patients with diabetes and coronary heart disease.

A total of 50 patients with type 2 diabetes and coronary heart disease who were treated in department of Cardiovascular Medicine of Huazhou People's Hospital from March 2019 to March 2020 were selected and randomly divided into treatment group and control group, 25 cases in each group, of which dapagliflozin was used in the treatment group Combined with metformin to interfere with blood glucose, the control group was treated with metformin. The two groups of patients were compared before the intervention and 6 months after the intervention for oxidative stress indicators (TAC, SOD, MDA), lipid metabolism indicators (TG, TC, LDL-C, HDL-C) and glucose metabolism indicators (HbAlc, FPG, 2hPG, fasting C peptide).

There was no significant difference in the levels of TAC, SOD, and MDA between the two groups before intervention (P>0.05). The TAC and SOD levels of the 12-week intervention group were significantly higher than those of the control group, and the MDA level was significantly lower than the control group , The difference was statistically significant (P<0.05). After 12 weeks of intervention, the levels of TC, TG, LDL-C in the treatment group were significantly lower than those in the control group (P<0.05), and the HDL-C levels in the treatment group were significantly higher than those in the control group (P<0.05). After 12 weeks of treatment, the FPG and 2hPG and HbA1c levels of the treatment group were significantly lower than those of the control group, while the average C peptide level of the treatment group was significantly higher than that of the control group, the difference was statistically significant (P<0.05).

Dapagliflozin combined with metformin can significantly improve the body's ability to resist oxidative stress and improve the glucose and lipid metabolism of patients with diabetes and coronary heart disease.